This website uses cookies. By using the site you are agreeing to our Privacy Policy.


HOME >> Investor Relations >> Top Message >> Message Archive (October 30, 2018)

PRINT

To Our Investors

I would like to express my sincere appreciation to all shareholders who support Japan Tissue Engineering (J-TEC). I will report below the company’s most recent developments. I don’t know where the time has gone, but it has already been a year since I became President and CEO. I would therefore like to take this opportunity to restate our initiatives over this year.

Reflections on this year

When I first took this job, l likened managing the company to a triple jump. Getting results into the black was the “hop,” and we have now adopted several policies as the “step” ahead of a real “jump.”

The first thing to do is to improve the value of our existing products and promote sales. We have made a partial change application to expand the indications for autologous cultured epidermis JACE to hereditary bullous epidermolysis. In addition, for autologous cultured cartilage JACC, we have made a partial change application for a human collagen film for use during transplantation to make surgery easier.

We have also sought out a plethora of new growth strategies. As a new initiative for autologous culture epidermis, I would like to realize a treatment for Leukoderma as part of esthetic skin treatment. Regarding autologous cultured cartilage JACC, we have applied to implement clinical trials to enable use for secondary knee osteoarthritis from trauma in more people. We will achieve these things at an early stage. Furthermore, we have also begun an attempt to treat leukemia using CAR-T cells in collaboration with Nagoya University. With development competition between large pharmaceutical manufacturers becoming more severe, we will make sound preparations using our unique methods for dealing with patients’ own cells.

From the “step” to the “jump”

This year has gone by really quickly. The Japanese regulatory environment around regenerative medicine has improved greatly, and we are now entering the stage at which corporate efforts would be desired. It is our duty to formulate a business model and increase predictability as a business. I have reconfirmed the need for greater efforts to enable all our stockholders to keep a close watch over our growth with an easy heart.

Under the prevailing conditions, now is the time to go on the offensive, and we have put in place a development lineup of various products in quick succession. Our challenge as a company involved in regenerative medicine is to manage the company with an eye on staying in the black while maintaining a pipeline of this size. After 20 years of groping about in the dark, this regenerative medicine company has finally started to see ahead. We have achieved the “step” I mentioned earlier, and we pledge to move onto the “jump” in the near future. Thank you for all your support.

5th TERMIS World Congress - 2018 Kyoto, Japan

5th TERMIS World Congress - 2018 Kyoto, Japan

October 30, 2018
Kenichiro Hata
President & CEO
Japan Tissue Engineering Co., Ltd.